Shenzhen Oral History ｜ Miao Xiang: Enterprises and SARs with 30 years of heart to protect everyone's life and health

Oral time: August 26, 2022

Oral location: Shenzhen Kangtai Biological Products Co., Ltd.

Seedlings

Born in 1973, a master's degree in accounting at Sun Yat -sen University, a Chinese registered accountant. Former heads of the International Business Department and Audit Department of the Guangzhou Branch of the Agricultural Bank of China, and the head of the financial center of Guangdong Zhujiang Investment Co., Ltd. and the Finance Center of Guangdong Zhujiang Investment Holding Co., Ltd. He joined Shenzhen Kangtai Biological Co., Ltd. in 2009, and is currently a director and president of Kangtai Biology. Miao Xiang has a wealth of corporate management experience, leading the company to establish "Shenzhen New Vaccine Engineering Laboratory", "Guangdong Provincial Treatment of hepatitis B vaccine engineering laboratory", "Research in Beijing Key Laboratory in Combination of Vaccine New Technology", "New Vaccine Beijing, Beijing Engineering laboratory "" engineering laboratory "and other R & D laboratories. Successfully dominated Kangtai Biological Lumping in the capital market, realized the listing of A shares, and promoted the company to complete multiple rounds of refinancing. In May 2021, he was elected as the representative of the 7th National People's Congress of Shenzhen; the vice president of the China Vaccine Industry Association.

In recent years, Shenzhen has formed a group of leading enterprises such as Nanshan High -tech Industrial Park, Pingshan National Biological Industry Base as dual -core, and coordinated development of other areas. Innovative enterprises. The reason why Kangtai New Crown Vaccine can quickly develop and produce and develop and produce in Shenzhen's complete biomedical industry chain and industrial ecology. Many R & D and production resources can be "located" in the Shenzhen biomedical ecosystem. Important factor in production. In the face of the future, Kangtai Bio will develop better vaccines to ensure people's health as the top priority and develop more high -quality innovative vaccines.

one

In Shenzhen, whether it is the government and the enterprise, or everyone who lives here, gives me a sense of aggressive, tolerant, full of vitality.

Reform and innovation allowed Shenzhen to develop rapidly

I was born and grown in Henan. I did n’t leave my hometown until I was admitted to college and came to school in Guangdong. Among them, the Pearl River Investment Company is a comprehensive enterprise, with a wide range of faces and a lot of industries. I have also grown rapidly from it.

Before coming to Guangdong, I had heard of Shenzhen, a city known as the "China's reform and opening up". During work in Guangzhou, I have also come to Shenzhen many times. Reform and innovation allowed this young city to develop rapidly, and each time I can bring me a different feeling. At that time, our business was all over the country, and the company's management reached a "intuitive" judgment: if one of our new businesses could not be done in Shenzhen, then we will basically do One of our new businesses cannot do it in other cities in China, and maybe we can get it in Shenzhen to try it.

Optimistic about industry development prospects

Choose to join Kangtai

In 2008, I learned that Kangtai is a company in Shenzhen Special Economic Zone. The development prospects of enterprises and industries have also been recognized by many people. Although I have some heartbreaking, it is still difficult to make choices. At that time, I have worked in Guangzhou for many years and are familiar with the living circle there. After a period of thinking and in -depth understanding of Kang Tai, in early 2009, I officially joined Kangtai as the company's financial leader.

In addition to being optimistic about the future development prospects of this industry, there are also the public welfare attributes of the vaccine "benefit the country and the people". More importantly, in Shenzhen, whether it is the government and the enterprise, or living here to work hard here, work hard and work hard here. Everyone in everyone gave me a sense of aggressive, tolerant, full of vitality. I believe that Shenzhen is a city that can achieve dreams and can make people do a career.

two

While the company consistently adheres to the "lifeline" of the product quality, it also needs to respond to various questions from the public and the media in time to the public and media to avoid unnecessary "shocks" to the enterprise and the entire industry.

Introduction to genetic reorganization B vaccine

In the late 1980s and early 1990s, due to the relatively backward medical conditions, the carrying rate of hepatitis B virus in my country was nearly 10%, especially the maternal and infant vertical transmission was more serious. During this period, the first generation of hepatitis B vaccine was developed in China. In this era, Kangtai Bio, who was reorganized in 1992, assumed an important historical mission, to introduce genetic reorganization of hepatitis B vaccine.

At that time, the Ministry of Health was led by the Ministry of Health. Kang Tai, as one of the two companies that undertake the genetic reorganization of genetic reorganization of genetic reorganization in China. The company sent a team to overseas to comprehensively study and introduce international advanced technologies. The members of our team at the time were very young. Everyone was holding a sense of historical mission to contribute to the country and winning the future of the industry. Back to China.

After 10 years of hard work, we have developed the world's exclusive 60UG hepatitis B vaccine for adult vaccination for low immunization and non -answering adults. In addition, the company's continuous production of hepatitis B vaccine is a variety of immunization planning for free vaccination for newborns for newborns, which has made great contributions to blocking the spread of hepatitis B mother and baby.

Strong vaccine production is based on quality

When I first joined Kangtai, the company only had the breed of hepatitis B vaccine. The product expansion and overall development were still stable, but the product diversified competitiveness was still insufficient. I thought that as a Shenzhen company that contributed so much to society, Kang Tai had to do his best to help the company do better. When we cheer up and prepare for a career, the company faces a sudden challenge. In November 2013, there were cases of severe adverse reactions caused by suspected injection of hepatitis B vaccine due to injection of hepatitis B vaccine. Within a month, the main plans to be immunoaged by Shenzhen Kangtai, including Shenzhen, have been involved in and discontinued production, and Kangtai, who occupies the largest market, has affected the most.

Is the continuous "occasional incident" still within a reasonable range? After a period of investigation, Kangtai's products confirmed that there was no quality problem. On January 3, 2014, the State Drug Administration officially reported that the hepatitis B vaccine produced by Shenzhen Kangtai Biological does not have quality problems, which meets the enterprise registration standards and national pharmacopoeia standards. The conclusion of this survey is also recognized by the World Health Organization.

Through this incident, we are more deeply aware that while the company consistently adheres to the "lifeline" of the product quality, it also needs to respond to the public and the media's various questions about the vaccine industry in a timely manner to avoid bringing the company or even the entire industry. The necessary "shock". In the next few years, we continue to consolidate the construction of the quality management system. The company's production base has successively passed the EU QP audit, the Philippines and other countries in GMP certification, and the quality management system has been internationally recognized.

Three

Kangtai's factory construction and vaccine research and development, production, and listing are the efficient cooperation and effort of relevant departments in Shenzhen, helping the vaccine to develop production and epidemic racing and racing with time.

In response to the country's call to participate in the research and development of the new crown vaccine

In December 2019, the epidemic in the new coronary pneumonia occurred. The epidemic was aggressive and spread to many places across the country. As one of the strong domestic vaccine companies, Kangtai quickly responded to the country's call and started vaccine research and development at the fastest speed. Normally, a vaccine takes about 10 years from research and development to listing. In addition to various clinical trials in the middle, it must be supervised by multiple national ministries and commissions. In terms of funds, the research and development cost of enterprises is as high as 1 billion yuan.

At that time, no one knew the development of the new crown pneumonia's epidemic situation, and would disappear naturally like SARS did not wait until the vaccine was developed. Or like the R & D of AIDS vaccines, it has been in terms of tens of billions of dollars worldwide, invested tens of billions of dollars, and has not yet been successful in research and development. Although facing all kinds of unknown, time is not allowed to think so much. The company's senior management has made decisions. As the most important public health product, vaccines determine its natural attributes of "it is preparation and not available, unavailable but not available". Essence

Rand against time

Ensure that the vaccine is successful as soon as possible

Since Kangtai has invested in the research and development of the new crown vaccine, the Shenzhen Nanshan District Committee and the district governments have quickly acted to discover the project's best construction ideas and implementation paths, organize special classes to settle in, on -site office and advance services. The Shenzhen Municipal Development and Reform Commission guided the completion of the workshop design planning and land use approval, and helped us obtain the P3 workshop construction approval from the National Development and Reform Commission. The joint guarantee projects were successfully completed in 116 days, creating the "Shenzhen speed" of the construction of anti -epidemic projects. Later, at various stages of the clinical approval, emergency use, material supply, warehousing and logistics, etc.

Since launching the new crown vaccine research and development, all our Kangtai executives and employees have more than 300 days and nights. They have been eating and accommodation in the factory area. After the successful operation, we mixed up more than 400 employees from the Beijing subsidiary to support the production and construction. They gave up their small homes and for everyone to stick to their positions. Three shifts in 24 hours to ensure the continuous supply of vaccines and meet the needs of the province and the country. At the same time, the company also does everything to solve the difficulties encountered by the family for these employees, such as arranging employees who have reached the company to stay in the company's suite apartment, coordinate the school for some employees' school -age children, etc., dispel their worries, and be the country. Dedication of the overall situation of epidemic prevention.

The new crown vaccine independently developed and produced in Shenzhen

In April 2021, the clinical trial data of Phase I/II of Kangtai Biological Coronatte Viruses was published at Yale University, Lengquan Port Labs, British Medical Journal, and the English version of "Chinese Medical Magazine". Data show that the protection rate of the vaccine is exceeded 90%, and there is no serious adverse reaction of level 3 or more. The overall adverse reaction incidence is significantly different from the placebo group, and it has good effectiveness and safety.

In May of the same year, the State Council ’s joint prevention and control mechanism officially approved the emergency use of the Kangtai Biological New Crown Vaccine, and passed the inspection of the issuance to formally supply the market. As the first new crown vaccine variety approved for emergency use in Guangdong Province, Kangtai's factory construction and the development, production, and listing of vaccines are efficient collaboration and cooperation in Shenzhen. Jack of microcosm.

On June 1, 2021, the first batch of new crown vaccines independently developed and produced by Kangtai were transported to each vaccination point to provide vaccination for Shenzhen citizens. At the "Kangtai Biological New Crown New Crown Vaccination Ceremony" held at the Shenzhen Bay Sports Center, Du Weimin, chairman of Kangtai Bio, and company executives took the lead in vaccination to pass confidence to the new vaccine. At the beginning, our Kangtai vaccine mainly met Guangdong's vaccination needs. Later, after the production capacity was improved, it also realized the gradual meetings of the country. ▲ On June 1, 2021, Shenzhen citizens lined up in vaccination with Kangtai Bio.

Unrestrained

Kangtai and Shenzhen came along all the way. In 30 years, they witnessed the "Shenzhen Development, Shenzhen Speed", witnessed Shenzhen's gradual development into a scientific and technological innovation center. The high -tech industries have flourished and innovative enterprises have emerged from the endless Hua Cai butterfly.

Go overseas to conduct new crown vaccine phase III clinical research

The new crown vaccine is a new vaccine, and the virus is also constantly mutating. We need to continue to test whether the vaccine is effective in actual combat. This requires our colleagues to go overseas, especially countries with serious epidemics to do clinical experiments. Starting in October last year, Comrade Liu Kai of the Ministry of Medicine of the Company went to the Philippines, Ukraine and other places to carry out the company's new crown and activated vaccine phase III clinical research site. In addition to facing the virus, the research team also experienced various dangers overseas. Among them, Liu Kai experienced the 14 -level typhoon "Rey" attack at the Balawwa Research Center in the Philippines. The communication signal was interrupted. The aircraft and ships were broken. During the exchanges of the Kyiv Research Center of Ukraine, the Russian -Ukraine conflict broke out. In order to complete the final on -site work, Liu Kai had shifted to a hotel with air defense facilities in a panic and chaos. Despite the hardships, fortunately, the team members returned to China safely, and clinical research continued to advance.

The new crown pneumonia's epidemic is still severe, which has a great impact on the production of people's lives. However, for Kangtai, after more than two years of the epidemic, the company has been fully exercised in all aspects of the company. On the one hand, we have enhanced emergency research and development capabilities. The average R & D cycle of traditional vaccines is 7 to 10 years, but the new crown belongs to major public health emergencies globally. The departments actively communicate and cooperate with their strengths to make up for the shortcomings of the enterprise with the resources of the national scientific research platform, and respond to the large -scale needs of the society with large -scale production in enterprises. On the other hand, the company's internationalization capabilities have been improved. The new crown vaccine produced by Kangtai's self -produced adenovirus carrier, through the introduction of advanced foreign technology and realizing localized production, feed the supply of developing countries, represents Guangdong and Shenzhen, and helps the country to practice to the world to the world The solemn commitment of providing 2 billion doses of the new crown vaccine shows the responsibility of the great country.

Develop better vaccines

Guard the health of the people

Kangtai and Shenzhen came along all the way. In 30 years, they witnessed the "Shenzhen Development, Shenzhen Speed", witnessed Shenzhen's gradual development into a scientific and technological innovation center. The high -tech industries have flourished and innovative enterprises have emerged from the endless Hua Cai butterfly. Since the bell was listed in September 2017, as a company dominated by R & D, Kang Tai developed rapidly in the first -class business environment in Shenzhen. New crown vaccines, adenovirus vector new crown vaccines and other varieties are listed or urgently used at home or overseas. Today, Kangtai's production scale is gradually moving towards the forefront of the same industry in China. It has 5 major industrial bases including Shenzhen and Beijing, which basically covers the world's mainstream vaccine types of research and development planning. The industrialization strength is the strongest in South China.

For more than 10 years in Kangtai, I have witnessed the continuous high -speed and glorious growth of the enterprise. What I am most impressed by is the "doing things and being honest and honest" that our chairman Du Weimin has been hanging on his mouth. This is also Kangtai Enterprise. At the core of culture, from the executives to the grass -roots employees, everyone is working hard to do the same goal, and to do a good job of vaccination and production, the quality is meticulous. Facing the future, Kangtai will continue to work with "creating better vaccines, benefiting human health", with quality and safety as the foundation, the power of research and development innovation, and to build a domestic first -class and internationally renowned large biopharmaceutical multinational company. Guarding the health of the people to make its own contribution.

Product: Shenzhen CPPCC Shenzhen Evening News Agency

General planning: Lin Jie

Study: Qiao Hengli

Supervision: Yin Changlong King Lei Ye Xiaobin

Guke: Huang Ling's unconventional: Lin Hang Zhao Qing Chen Li

Executive: Wang Shuo Cheng Gong Zheng Shuqi Deng Jingmin Zhu Changhuan

Writing and writing: Shenzhen Evening News reporter Qiu Zhidong

- END -